What is Codexis?
Headquartered in Redwood City, California, Codexis operates at the intersection of biotechnology and industrial efficiency. The company specializes in the discovery and development of high-performance enzymes and proteins that are critical to the production of small molecule pharmaceuticals and nucleic acid-based medicines. By utilizing its proprietary CodeEvolver platform, Codexis enables its partners to achieve superior manufacturing yields while simultaneously reducing energy consumption and waste. This commitment to sustainable chemistry has earned the firm significant industry recognition, including the Presidential Green Chemistry Challenge Award. Beyond its core enzyme business, the company is aggressively expanding its ECO Synthesis platform, which is designed to facilitate the scalable, enzymatic manufacturing of RNAi therapeutics, positioning Codexis as a vital link in the global pharmaceutical supply chain.
How much funding has Codexis raised?
Codexis has raised a total of $160M across 4 funding rounds:
Series D
$37M
Stock Offering
$78M
Stock Offering
$5M
Debt
$40M
Series D (2006): $37M with participation from CMEA Ventures, Chevron, Pequot Ventures, Bio*One Capital, and Maxygen
Stock Issuance/Offering (2010): $78M, investors not publicly disclosed
Stock Issuance/Offering (2019): $5M supported by Casdin Capital
Debt (2024): $40M featuring Innovatus Capital Partners
Key Investors in Codexis
CMEA Ventures
A San Francisco-based venture capital firm specializing in science-based investments across life sciences, high technology, and energy sectors.
Chevron
A global integrated energy corporation with extensive operations in chemicals and renewable fuels, focusing on long-term industrial innovation.
Innovatus Capital Partners
An investment firm focused on asset-based financing and capital solutions, targeting opportunities created by market volatility and industrial disruption.
What's next for Codexis?
With the recent strategic financing, Codexis is well-positioned to accelerate the commercialization of its ECO Synthesis platform and deepen its penetration into the rapidly evolving biotherapeutics market. The company's strategic roadmap focuses on scaling its protein engineering capabilities to meet the increasing demand for complex, high-value pharmaceutical ingredients. By maintaining a focus on high-performance, sustainable manufacturing solutions, Codexis is poised to capitalize on the shift toward greener, more efficient production methodologies in the life sciences sector. Investors and industry analysts will be closely monitoring the company's ability to translate this capital into expanded market share and sustained operational excellence in the coming fiscal periods.
See full Codexis company page
